Clinical Trial

Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

Study acronym: PROMISS-DKD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-29; most recent amendment 2025-07-14.
Status change: Not Yet Recruiting → Recruiting 2025-07-14
Trial Details
NCT Number NCT06962098
Lead Sponsor Aptabio Therapeutics, Inc.
Conditions Diabetic Kidney Disease (DKD)
Enrollment 186 participants
Start Date 2025-05-26
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-18